IN2014MU01283A - - Google Patents
Download PDFInfo
- Publication number
- IN2014MU01283A IN2014MU01283A IN1283MU2014A IN2014MU01283A IN 2014MU01283 A IN2014MU01283 A IN 2014MU01283A IN 1283MU2014 A IN1283MU2014 A IN 1283MU2014A IN 2014MU01283 A IN2014MU01283 A IN 2014MU01283A
- Authority
- IN
- India
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1283MU2014 IN2014MU01283A (pt) | 2014-04-04 | 2014-04-04 | |
| US14/677,110 US9351957B2 (en) | 2014-04-04 | 2015-04-02 | Amorphous form of apremilast |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1283MU2014 IN2014MU01283A (pt) | 2014-04-04 | 2014-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MU01283A true IN2014MU01283A (pt) | 2015-10-09 |
Family
ID=54208812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN1283MU2014 IN2014MU01283A (pt) | 2014-04-04 | 2014-04-04 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US9351957B2 (pt) |
| IN (1) | IN2014MU01283A (pt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9765026B2 (en) | 2015-08-28 | 2017-09-19 | Scinopharm Taiwan, Ltd. | Forms of apremilast and the process of making the same |
| WO2017076987A1 (en) * | 2015-11-03 | 2017-05-11 | Ratiopharm Gmbh | Composition comprising apremilast in amorphous form |
| CN106727344A (zh) * | 2015-11-19 | 2017-05-31 | 常州爱诺新睿医药技术有限公司 | 一种无定型阿普斯特的固体分散体及其制备方法 |
| WO2017084597A1 (zh) | 2015-11-19 | 2017-05-26 | 常州爱诺新睿医药技术有限公司 | 一种阿普斯特的无定型物、其制备方法及应用 |
| CN105548393A (zh) * | 2015-12-14 | 2016-05-04 | 成都百裕制药股份有限公司 | 一种检测阿普斯特原料中杂质含量的方法 |
| CZ20165A3 (cs) * | 2016-01-06 | 2017-07-19 | Zentiva, K.S. | Způsoby přípravy amorfního apremilastu |
| WO2017175087A1 (en) * | 2016-04-08 | 2017-10-12 | Intas Pharmaceuticals Ltd. | Process for preparation of amorphous apremilast |
| CN109310624A (zh) | 2016-06-15 | 2019-02-05 | 托伦特药物有限公司 | 阿普斯特的局部组合物 |
| US10196355B2 (en) | 2016-06-20 | 2019-02-05 | Johnson Matthey Public Limited Company | Forms of apremilast |
| WO2019116386A1 (en) * | 2017-12-12 | 2019-06-20 | Alkem Laboratories Ltd. | Oral pharmaceutical compositions of amorphous apremilast and process for preparing thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6020358A (en) | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
| US6962940B2 (en) | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
| US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| MX2010010454A (es) | 2008-03-27 | 2010-12-20 | Celgene Corp | Formas solidas que comprenden (+)-2-[1-(3-etoxi-4-metoxifenil)-2-m etilsulfoniletil]-4-acetilaminoisoindolina-1,3-diona, composiciones de la misma y usos de la misma. |
| US9045417B2 (en) | 2011-01-14 | 2015-06-02 | Celgene Corporation | Isotopologues of isoindole derivatives |
| AR090100A1 (es) | 2012-02-21 | 2014-10-22 | Celgene Corp | Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina |
| US8981117B2 (en) | 2012-09-14 | 2015-03-17 | Celgene Corporation | Processes for the preparation of isoindole compounds and isotopologues thereof |
| EP2730278A1 (en) | 2012-11-08 | 2014-05-14 | Ratiopharm GmbH | Composition melt |
-
2014
- 2014-04-04 IN IN1283MU2014 patent/IN2014MU01283A/en unknown
-
2015
- 2015-04-02 US US14/677,110 patent/US9351957B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US9351957B2 (en) | 2016-05-31 |
| US20150283249A1 (en) | 2015-10-08 |